MASH Management Adipose Tissue

CE / CME

A Metabolic Approach to MASH Management: Adipose Tissue as a Metabolic Organ

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: December 12, 2023

Expiration: December 11, 2024

Mazen Noureddin
Mazen Noureddin, MD, MHSc

Activity

Progress
1
Course Completed

References

 

  1. Kahn CR, Wang G, Lee KY. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 2019;129:3990-4000.
  2. Chakrabarti P, Kim JY, Singh M, et al. Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway. Mol Cell Biol. 2013;33:3659-3666
  3. Lemoine M, Ratziu V, Kim M, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009;29:1431-1438.
  4. Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol. 2013;19:802-812.
  5. Formolo DA, Cheng T, Yu J, et al. Central adiponectin signaling - a metabolic regulator in support of brain plasticity. Brain Plast. 2022;8:79-96. 
  6. Roy B, Palaniyandi SS. Tissue-specific role and associated downstream signaling pathways of adiponectin. Cell Biosci. 2021;11:77.
  7. Gastaldelli A, Harrison S, Belfort-Aguiar R, et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther. 2010;32:769-775.
  8. Pennisi G, Pipitone RM, Enea M, et al. A genetic and metabolic staging system for predicting the outcome of nonalcoholic fatty liver disease. Hepatol Commun. 2022;6:1032-1044.
  9. De Vincentis A, Tavaglione F, Jamialahmadi O, et al. A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol. 2022;20:658-673.
  10. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774-788.
  11. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519-1523. 
  12. Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 2020;3:e00112.
  13. Yen PC, Chou YT, Li CH, et al. Hyperuricemia is associated with significant liver fibrosis in subjects with nonalcoholic fatty liver disease, but not in subjects without it. J Clin Med. 2022;11:1445.
  14. Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 2019;1:312-328.
  15. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2012;56:234-2340. 
  16. Nevola R, Epifani R, Imbriani S, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023;24:1703.